Author

Alessio Turolla

Observed name: A Turolla

Institution: Newron Pharmaceuticals (Italy)

Observed institution: Newron Pharmaceuticals (Italy)

ORCID: 0009-0005-2167-6143

Observed ORCID: 0009-0005-2167-6143

OpenAlex ID: A5039729144

Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia

2023 · Ravi Anand, Alessio Turolla, et al. · The International Journal of Neuropsychopharmacology · 23

Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial

2024 · Ravi Anand, Alessio Turolla, et al. · Neuropharmacology · 16

Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical Trial

2024 · Ravi Anand, Alessio Turolla, et al. · The International Journal of Neuropsychopharmacology · 10

Galvanic Displacement of Nanostructured Gold for Flavoenzyme Adsorption in Biotechnology

2011 · Luca Magagnin, Paula Cojocaru, et al. · ECS Transactions · 5

Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trials

2026 · Ravi Anand, Alessio Turolla, et al. · Therapeutic Advances in Psychopharmacology · 2

Galvanic Displacement of Nanostructured Gold for Flavoenzyme Adsorption in Biotechnology

2010 · Luca Magagnin, Paula Cojocaru, et al. · ECS Meeting Abstracts · 1

545. Targeting negative and cognitive symptoms in schizophrenia: discussion of novel preclinical and clinical findings with evenamide

2026 · R Anand, A Turolla, et al. · The International Journal of Neuropsychopharmacology

526. Translating glutamate modulation into clinical advances for patients with treatment-resistant schizophrenia: challenges and updates from the ENIGMA-TRS phase 3 program

2026 · R Anand, A Turolla, et al. · The International Journal of Neuropsychopharmacology

Evenamide as Add-on Treatment for Patients With Chronic Schizophrenia Not Responding Adequately to Their Current Antipsychotic Medication: Results of a Potentially Pivotal, Phase Ii/iii, International, Randomized, Double Blind, Placebo- Controlled Trial

2025 · *Ravi Anand, Alessio Turolla, et al. · The International Journal of Neuropsychopharmacology

Evenamide as Add-on Treatment for Treatment-resistant Schizophrenia (trs) Patients Not Benefiting From Antipsychotics: Design of a Phase 3, Potentially Pivotal, International, Randomized, Double-blind, Placebo-controlled Clinical Trial

2025 · *Ravi Anand, Alessio Turolla, et al. · The International Journal of Neuropsychopharmacology

Remarkable Efficacy of Evenamide, a Glutamate Antagonist, as an Add-on to Antipsychotics in Patients With Treatment Resistant Schizophrenia (trs): Results From a One-year, Open- Label, Dose-comparative, Randomized, Treatment Trial

2025 · *Ravi Anand, Alessio Turolla, et al. · The International Journal of Neuropsychopharmacology

Evenamide, as an Add-on to Antipsychotics, Produces Long- Lasting Clinically Meaningful Benefit and Converts Treatment- Resistant Schizophrenia (trs) Patients Into a Responsive State: 6-month Results From an Ongoing International Randomized Study

2025 · *Ravi Anand, Alessio Turolla, et al. · The International Journal of Neuropsychopharmacology

Works count: 12

Citation count: 57

H-index: 4

I10-index: 3